Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04508530 · ClinicalTrials.gov registry record · Phase 3
Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
A Phase 3 study, sponsored by Octapharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 71
- Enrollment target
NCT04508530 is a Phase 3 study that has completed, run by Octapharma. The registered enrollment target is 71 participants.
The verdict
NCT04508530, a Phase 3 study, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 71 participants
- Enrollment target
Study Summary
A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome
Interventions
- OTHER Placebo
- BIOLOGICAL Panzyga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04508530
The ClinicalTrials.gov registry entry for NCT04508530 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04508530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04508530 about?
NCT04508530 is a clinical study titled "Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)". A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome
What is the current status of trial NCT04508530?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 71 participants. The study started on 2021-06-30. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT04508530?
The interventions under investigation include: Placebo (OTHER), Panzyga (BIOLOGICAL).
Who is sponsoring clinical trial NCT04508530?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.